A pilot study of pNGVL4a-CRT/E7(detox) for the treatment of patients with HPV16 + cervical intraepithelial neoplasia 2/3 (CIN2/3)
详细信息 查看全文
- 作者：Ronald D. Alvareza ; rdalvarez@uab.edu" class="auth_mail" title="E-mail the corresponding author ; Warner K. Huha ; Sejong Baea ; Lawrence S. Lamb Jra ; Michael G. Connera ; Jean Boyerb ; Chenguang Wangc ; Chien-Fu Hungc ; Elizabeth Sauterc ; Mihaela Paradisc ; Emily A. Adamsc ; Shirley Hestera ; Bradford E. Jacksona ; T.C. Wuc ; Cornelia L. Trimblec
- 关键词：Cervical dysplasia ; Therapeutic DNA vaccine
- 刊名：Gynecologic Oncology
- 出版年：2016
- 出版时间：February 2016
- 年：2016
- 卷：140
- 期：2
- 页码：245-252
- 全文大小：826 K
文摘
- •
The therapeutic HPV DNA vaccine pNGVL4a-CRT/E7(detox) can be administered safely.
- •
The Immune response was most robust when vaccinated directly into the cervix.
- •
Histologic regression to ≤ CIN 1 was noted in 30% of vaccinated CIN 2/3 patients.